tetano
Editor, Senior Moderator
Biochem Pharmacol. 2013 Sep 23. pii: S0006-2952(13)00600-X. doi: 10.1016/j.bcp.2013.09.010. [Epub ahead of print]
DANCING WITH CHEMICAL FORMULAE OF ANTIVIRALS: A PANORAMIC VIEW (part 2).
De Clercq E.
Source
Rega Institute for Medical Research, KU Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium. Electronic address: erik.declercq@rega.kuleuven.be.
Abstract
In this second part of "Dancing with antivirals as chemical formulae" I will focus on a number of chemical compounds that in the last few years have elicited more than common attraction from a commercial viewpoint: (i) favipiravir (T-705), as it is active against influenza, but also several other RNA viruses; (ii) neuraminidase inhibitors such as zanamivir and oseltamivir; (iii) peramivir and laninamivir octanoate, which might be effective against influenza virus following a single (intravenous or inhalation) administration; (iv) sofosbuvir, the (anticipated) cornerstone for the interferon-free therapy of HCV infections; (v) combinations of DAAs (direct antiviral agents) to achieve, in no time, a sustained virus response (SVR) against HCV infection; (vi) HIV protease inhibitors, the latest and most promising being darunavir; (vii) the integrase inhibitors (INIs) (raltegravir, elvitegravir, dolutegravir), representing a new dimension in the anti-HIV armamentarium; (viii), a new class of helicase primase inhibitors (HPIs) that may exceed acyclovir and the other anti-herpes compounds in both potency and safety; (ix) CMX-001, as the latest of Dr. Anton?n Hol?'s legacy for its activity against poxviruses and CMV infections, and (x) noroviruses for which the ideal antiviral compounds are still awaited for.
Copyright ? 2013. Published by Elsevier Inc.
KEYWORDS:
CMX-001, CMX-001 (PubChem CID: 483477), Daclatasvir (PubChem CID: 25154714), Direct acting antivirals (DAAs), Dolutegravir (PubChem CID: 54726191), Elvitegravir (PubChem CID: 5277135), Favipiravir, Favipiravir (PubChem CID: 492405), HIV protease inhibitors (PIs), Helicase primase inhibitors (HPIs), Integrase inhibitors (INIs), Laninamivir octanoate (PubChem CID: 9847629), Ledipasvir (PubChem CID: 67505836), Neuraminidase inhibitors, Norovirus, Oseltamivir (PubChem CID: 65028), Peramivir (PubChem CID: 154234), Raltegravir (PubChem CID: 54671008), Sofosbuvir, Sofosbuvir (PubChem CID: 45375808), Zanamivir (PubChem CID: 60855)
PMID:
24070654
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24070654
DANCING WITH CHEMICAL FORMULAE OF ANTIVIRALS: A PANORAMIC VIEW (part 2).
De Clercq E.
Source
Rega Institute for Medical Research, KU Leuven, Minderbroedersstraat 10, B-3000 Leuven, Belgium. Electronic address: erik.declercq@rega.kuleuven.be.
Abstract
In this second part of "Dancing with antivirals as chemical formulae" I will focus on a number of chemical compounds that in the last few years have elicited more than common attraction from a commercial viewpoint: (i) favipiravir (T-705), as it is active against influenza, but also several other RNA viruses; (ii) neuraminidase inhibitors such as zanamivir and oseltamivir; (iii) peramivir and laninamivir octanoate, which might be effective against influenza virus following a single (intravenous or inhalation) administration; (iv) sofosbuvir, the (anticipated) cornerstone for the interferon-free therapy of HCV infections; (v) combinations of DAAs (direct antiviral agents) to achieve, in no time, a sustained virus response (SVR) against HCV infection; (vi) HIV protease inhibitors, the latest and most promising being darunavir; (vii) the integrase inhibitors (INIs) (raltegravir, elvitegravir, dolutegravir), representing a new dimension in the anti-HIV armamentarium; (viii), a new class of helicase primase inhibitors (HPIs) that may exceed acyclovir and the other anti-herpes compounds in both potency and safety; (ix) CMX-001, as the latest of Dr. Anton?n Hol?'s legacy for its activity against poxviruses and CMV infections, and (x) noroviruses for which the ideal antiviral compounds are still awaited for.
Copyright ? 2013. Published by Elsevier Inc.
KEYWORDS:
CMX-001, CMX-001 (PubChem CID: 483477), Daclatasvir (PubChem CID: 25154714), Direct acting antivirals (DAAs), Dolutegravir (PubChem CID: 54726191), Elvitegravir (PubChem CID: 5277135), Favipiravir, Favipiravir (PubChem CID: 492405), HIV protease inhibitors (PIs), Helicase primase inhibitors (HPIs), Integrase inhibitors (INIs), Laninamivir octanoate (PubChem CID: 9847629), Ledipasvir (PubChem CID: 67505836), Neuraminidase inhibitors, Norovirus, Oseltamivir (PubChem CID: 65028), Peramivir (PubChem CID: 154234), Raltegravir (PubChem CID: 54671008), Sofosbuvir, Sofosbuvir (PubChem CID: 45375808), Zanamivir (PubChem CID: 60855)
PMID:
24070654
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/24070654